SURPASS-CVOT: duello tirzepatide versus dulaglutide sugli outcome cardiovascolari nel T2DM - A cura di Angelo Cignarelli, Marella Marassi e Giovanni Antonio Silverii
Articolo di riferimento: Stephen J. Nicholls, M.B., B.S., Ph.D., Imre Pavo, M.D., Deepak L. Bhatt, M.D., M.P.H., John B. Buse, M.D., Ph.D., Stefano Del Prato, M.D., Steven E. Kahn, M.B., Ch.B., A. Michael Lincoff, M.D., +20, for the SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. Published December 17, 2025. N Engl J Med 2025;393:2409-2420. DOI: https://www.nejm.org/doi/10.1056/NEJMoa2505928